Business Context and Reporting Period
This Form 8-K is a current report filed by Milestone Pharmaceuticals Inc. on March 18, 2025. The filing addresses corporate governance matters, specifically the scheduling of the 2025 Annual Meeting of Shareholders and the deadlines for shareholder proposals and director nominations.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly procedural and contains no financial performance data.
Material Changes
The primary material change reported is the establishment of the date for the 2025 Annual Meeting of Shareholders. Because this date is more than 30 days from the anniversary of the 2024 annual meeting, the Company is required to file this report to inform shareholders of the change and provide specific submission deadlines.
Guidance, Outlook, and Management Commentary
- 2025 Annual Meeting Date: June 10, 2025.
- Record Date: April 15, 2025 (shareholders must be on record by this date to vote).
- Proposal Deadlines:
- Rule 14a-8 Proposals: Must be received by March 29, 2025.
- Quebec Business Corporations Act Proposals: Must be submitted by April 15, 2025.
- Universal Proxy Rule (Director Nominations): Notice must be provided by April 11, 2025.
- Location and Time: To be disclosed in the definitive proxy statement.
Investor Verification Checklist
- Verify the definitive proxy statement for the specific time and location of the June 10, 2025 Annual Meeting.
- Confirm share ownership status as of the April 15, 2025 record date to ensure voting eligibility.
- Review the specific requirements for Rule 14a-8 and Quebec Business Corporations Act proposals if intending to submit shareholder items.
- Note the April 11, 2025 deadline for submitting notices regarding director nominations under universal proxy rules.